Lung function and exercise capacity 6 months after hospital discharge for critical COVID-19

BMC Pulmonary Medicine

Table 2 Clinical characteristics and treatment of the 85 patients treated in intensive care units due to a SARS-CoV-2 infection

	N = 85
SOFA	6 (3–8)^a
SAPS II	27 (20–38)^b
APACHE II	17 (13–20)^c
Max FiO2, % (if not intubated)	60 (40–60)
High flow oxygen delivery	20 (24%)
NIV	3 (4%)
Invasive mechanical ventilation	55 (65%)
ECMO	0 (0%)
Renal replacement therapy	5 (6%)
Prone position	27 (32%)
Drug treatment
Antibiotics	85 (100%)
Oseltamivir^α	20 (24%)
Remdesivir	2 (2%)
Hydroxychloroquine	0 (0%)
Corticosteroids
Methylprednisolone with ARDS indication^β	8 (9%)
Dexamethasone	17 (20%)
Other corticosteroids	0 (0%)
Enoxaparin
Prophylactic dose^χ	68 (80%)
Therapeutic dose^δ	17 (20%)
Time from symptom onset to hospital admission, days	8 (6–10)
Time from symptom onset to ICU admission, days	10 (8–13)
Length of ICU stay, days
Intubated n = 55	15 (9–25)
Not intubated n = 30	4 (2–6)
All N = 85	9 (5–18)
Duration of invasive mechanical ventilation, days	12 (7–16)
Length of hospital stay, days	20 (15–27)

Data are median (IQR, interquartile range) or n (%)
SOFA, Sequential Organ Failure Assessment Score; SAPS II, Simplified Acute Physiology Score; APACHE II, Acute Physiology and Chronic Health Evaluation; ICU, intensive care unit; FiO2, fraction of inspired oxygen; NIV, non-invasive ventilation; ECMO, extracorporeal membrane oxygenation; ARDS, acute respiratory distress syndrome
^αOseltamivir was used during the early pandemic until influenza was excluded and SARS-CoV2-PCR test positivity was confirmed
^βMethylprednisolone loading dose 1 mg/kg, followed by a continuous infusion of 1 mg/kg/day
^χEnoxaparin at prophylactic dose < 1.5 mg/kg/day
^δEnoxaparin at therapeutic dose > 1.5 mg/kg/day
Data available for, % ^a79.6, ^b79.6, ^c75.3

ISSN: 1471-2466